MiniMed Group Reports Strong Sales, Raises Guidance; Submits Product to FDA
What happened
MiniMed Group reported first-quarter fiscal 2027 net sales of $843 million, representing a 16.6% rise reported. The company also raised its full-year organic revenue growth guidance to approximately 10.5%. Separately, MiniMed Fit was submitted to the FDA, with a full U.S. launch expected in summer 2027. UBS, Morgan Stanley, and Deutsche Bank among others raised their target prices for the company.
From insidermonkey.com
Why it matters
The strong sales performance and the raising of revenue guidance suggest positive momentum for MiniMed Group. The FDA submission of MiniMed Fit is cited by analysts as a key catalyst, pointing to potential future revenue streams in the diabetes and medtech sectors.
From insidermonkey.com
Who's involved
- UBSRaised target prices for MiniMed Group stock.
- Morgan StanleyRaised target prices for MiniMed Group stock.
- FDAReceived a product submission from MiniMed Group.
- Deutsche BankRaised target prices for MiniMed Group stock.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Morgan StanleySpeculative
Morgan Stanley could see changes in its segment business due to raising target prices on MiniMed Group stock.
- Deutsche BankSpeculative
Deutsche Bank could see changes in its segment business due to raising target prices on MiniMed Group stock.
Keep exploring
The entities involved
-
UBS
Swiss multinational investment bank and financial services company
-
Morgan Stanley
U.S. investment bank
- FDA
Related events
- Flex commercial launch is planned, FDA submission accelerates MiniMed Fit, and Instinct sensor launches in Western Europe.
- Victory Capital, Royal Bank of Canada, and Morgan Stanley released research notes and raised price targets on August 12, 2026.
- Morgan Stanley raised its target and UBS upgraded Eaton Corporation stock on September 8, 2026.